# Illumina Inc. (ILMN)

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ILMN/primer

## Business Model

---
source: coverage-next-full
ticker: ILMN
step: "01"
title: Business Overview — Illumina, Inc.
created: 2026-05-29
---

### Step 01 — Business Overview: Illumina, Inc. (ILMN)

#### Company Summary

Illumina, Inc. is the world's dominant provider of next-generation sequencing (NGS) technology, controlling an estimated 80%+ of the global NGS market. Founded in 1998 and headquartered in San Diego, California, the company designs, develops, manufactures, and markets integrated systems for genetic analysis — spanning instruments, consumables (reagent kits, flow cells), software, and services.

Illumina's technology underpins virtually every major advance in genomics: population-scale sequencing initiatives, oncology liquid biopsy tests, NIPT (non-invasive prenatal testing), pharmacogenomics, rare disease diagnosis, agricultural genomics, and microbiome research. Its platforms are embedded in thousands of labs across hospitals, universities, biopharma companies, and government programs globally.

---

#### Business Model

**Razor-and-Blade:** Illumina sells or places sequencing instruments (razors), then generates recurring, high-margin revenue from consumables — reagent kits and flow cells that customers must repurchase with each sequencing run (blades). Instruments are priced $10K–$1M+ depending on throughput; consumables generate ~70–72% of total revenue annually.

**Lock-In Dynamics:** Once a lab installs Illumina instruments, switching costs are extremely high:
- Retraining staff and revalidating workflows is costly and time-consuming
- Clinical labs face regulatory recertification if they switch platforms
- Decades of published scientific literature built on Illumina chemistry creates methodology lock-in
- DRAGEN bioinformatics software is deeply integrated into sequencing workflows

---

#### Segments and Product Lines

##### Reporting Structure
Post-GRAIL divestiture (June 2024), Illumina reports as a **single operating segment** (Sequencing). Revenue is broken out by product type and end market in disclosures.

##### Product Type Revenue (FY2025)
| Product Type | Revenue | % of Total |
|-------------|---------|-----------|
| Consumables | ~$3,040M | ~70% |
| Instruments | ~$780M | ~18% |
| Services | ~$523M | ~12% |
| **Total** | **$4,343M** | **100%** |

##### Key Platforms
| Platform | Use Case | Position |
|----------|----------|----------|
| **NovaSeq X / X Plus** | Ultra-high throughput (WGS, population sequencing, clinical) | Flagship; launched 2023; transformative cost reduction |
| **NovaSeq 6000** | High throughput; predecessor platform | Sunset/replacement cycle underway |
| **NextSeq 2000** | Mid-throughput (oncology panels, targeted sequencing) | Workhorse for clinical labs |
| **MiSeq / MiniSeq** | Low-throughput (targeted panels, amplicon sequencing) | Entry-level / benchtop |
| **iSeq 100** | Ultra-low throughput | Point-of-care/education |
| **DRAGEN** | On-instrument bioinformatics acceleration | Software differentiation |
| **SomaLogic SomaScan** | Proteomics (7,000–11,000 protein measurement) | New (acquired Jan 2026); multiomics strategy |

##### End Market Breakdown (FY2025 est.)
- **Clinical (~55%):** Oncology (somatic/germline), NIPT, rare disease, pharmacogenomics
- **Research (~45%):** Academic, government (NIH-funded), biopharma R&D

---

#### Geographic Revenue (FY2025 est.)
| Region | Revenue | % of Total | Growth YoY |
|--------|---------|-----------|-----------|
| Americas | ~$1,780M | ~41% | +3–4% |
| EMEA | ~$1,390M | ~32% | +2–3% |
| Asia-Pacific | ~$1,173M | ~27% | -5–8% (China drag) |
| **China (included above)** | ~$250M | ~6% | ~-20% (UEL impact) |

---

#### GRAIL Chapter (2021–2024)

The most defining event of recent Illumina history was the GRAIL saga:
- **Background:** GRAIL was founded by Illumina in 2016 as a spin-off focused on multi-cancer early detection using liquid biopsy. Illumina re-acquired GRAIL in August 2021 for ~$8.0B.
- **Regulatory opposition:** The FTC and EU Competition Commission opposed the acquisition. The EU blocked it outright; the FTC issued an administrative complaint. Illumina defied the EU Order — a historic confrontation that generated billions in fines and massive board/management distraction.
- **Board/CEO turnover:** CEO Francis deSouza resigned in June 2023 after shareholder pressure. Carl Icahn waged a proxy campaign, placing new board members. The board undertook a strategic review.
- **Divestiture:** In October 2023, Illumina announced it would divest GRAIL. The divestiture was completed June 24, 2024: 85.5% of GRAIL was spun off to Illumina shareholders as GRAIL stock (now trading NASDAQ: GRAL); Illumina retained ~14.5%.
- **Financial damage:** Cumulative impairments on GRAIL exceeded $4B. Operating losses from GRAIL 2021–2024 were substantial. The distraction cost Illumina strategic execution during a critical window of NovaSeq X launch.

---

#### Strategic Positioning Post-GRAIL

Under CEO Jacob Thaysen (appointed August 2023, permanent appointment March 2024):
1. **Focus on core sequencing:** Simplifying portfolio, driving NovaSeq X adoption
2. **Cost discipline:** R&D rationalized from 27% to 22% of revenue; SG&A flat
3. **Clinical acceleration:** Building out oncology, NIPT, and rare disease pathways
4. **Multiomics:** SomaLogic acquisition (closed Jan 2026) adds proteomics capability — positioning for integrated multi-omics workflows
5. **China mitigation:** Driving ex-China growth to offset ongoing headwinds from UEL designation

---

#### Key Customers
- Large genome centers (BGI/CNGB, Genomics England, Garvan Institute)
- Reference laboratories (LabCorp, Quest, Sonic Healthcare, Mayo Clinic)
- Hospital/health system labs (mass adoption for oncology testing)
- Academic research institutions (MIT, Broad Institute, Wellcome Sanger)
- Pharmaceutical and biotech companies (drug discovery, companion diagnostics)
- Government programs (NIH, UK Biobank, All of Us Research Program)

---

#### Competitive Position Summary
Illumina occupies a near-monopoly position in short-read NGS with ~80%+ market share. The company benefits from:
- 25+ years of installed base and consumable dependency
- Industry-standard chemistry (SBS — sequencing by synthesis)
- IP portfolio of 3,000+ patents
- Trusted brand in regulated clinical markets
- Scale advantages in manufacturing and R&D

## Financial Snapshot

---
source: coverage-next-full
ticker: ILMN
step: "04"
title: Financial Snapshot — 5-Year P&L Summary
created: 2026-05-29
---

### Step 04 — Financial Snapshot: 5-Year P&L Summary

#### Key Caveat: GRAIL Distortion
FY2021–FY2024 financials are heavily distorted by GRAIL (acquisition August 2021, divestiture June 2024). GAAP operating income and net income reflect massive impairment charges ($3.9B in FY2022, additional impairments in FY2023), GRAIL operating losses, and a disposal loss in FY2024 Q2. **Adjusted/core metrics are the most relevant for ongoing analysis.** FY2025 is the first clean year as a pure-play sequencing company.

---

#### Income Statement Summary (GAAP)

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM (Q1 2026) |
|--------|--------|--------|--------|--------|--------|--------------|
| Revenue | $4,526M | $4,584M | $4,504M | $4,372M | $4,343M | $4,393M |
| YoY Growth | +39% | +1.3% | -1.7% | -2.9% | -0.7% | +1.3% |
| Gross Profit | $3,154M | $2,972M | $2,744M | $2,861M | $2,870M | $2,908M |
| Gross Margin | 69.7% | 64.8% | 60.9% | 65.5% | 66.1% | 66.2% |
| R&D Expense | $(1,060M) | $(1,321M) | $(1,354M) | $(1,107M) | $(967M) | $(953M) |
| SG&A Expense | $(1,044M) | $(1,210M) | $(1,108M) | $(1,062M) | $(1,086M) | $(1,104M) |
| Operating Income (GAAP) | $(123M) | $(4,179M) | $(1,069M) | $(833M) | $807M | $851M |
| Operating Margin | (2.7%) | (91.2%) | (23.7%) | (19.1%) | 18.6% | 19.4% |
| Interest & Other | ~$(82M) | ~$(80M) | ~$(85M) | ~$(60M) | ~$(55M) | ~$(50M) |
| Tax | — | — | — | — | ~$(100M) | ~$(100M) |
| Net Income (GAAP) | $762M | $(4,404M) | $(1,161M) | $(1,223M) | $850M | $853M |
| Diluted EPS (GAAP) | $5.04 | $(28.00) | $(7.34) | $(7.69) | $5.45 | $5.52 |

**Notes on GAAP distortions:**
- FY2021 net income positive despite operating losses — reflects deferred tax benefits and other items
- FY2022 operating loss: includes ~$3.9B goodwill impairment on GRAIL
- FY2023 operating loss: includes ~$700M+ additional impairments and GRAIL operating losses
- FY2024 Q2 operating loss: ~$1.7B disposal loss on GRAIL divestiture
- FY2024 Q3 operating income spike ($741M in one quarter) reflects GRAIL derecognition gain

---

#### Adjusted (Non-GAAP) Operating Income — Core Business

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026E |
|--------|--------|--------|--------|--------|--------|---------|
| Revenue | $4,526M | $4,584M | $4,504M | $4,372M | $4,343M | ~$4,520M |
| Non-GAAP Gross Margin | ~70% | ~66% | ~64% | ~66% | ~68% | ~68-69% |
| Non-GAAP Operating Income | ~$1,200M | ~$1,050M | ~$850M | ~$950M | ~$1,050M | ~$1,200M |
| Non-GAAP Operating Margin | ~26% | ~23% | ~19% | ~22% | ~24% | ~26% |
| Non-GAAP EPS | ~$7.50 | ~$5.70 | ~$4.30 | ~$5.20 | ~$6.50 | ~$5.05–5.20 |

**Exclusions from Non-GAAP:** Stock-based compensation (~$300–400M/yr), amortization of acquired intangibles, GRAIL-related items, restructuring charges, impairments

---

#### Gross Margin Analysis

| Driver | Direction | Magnitude |
|--------|-----------|-----------|
| GRAIL consolidation (FY2022-Q2 2024) | Dilutive | ~300–500 bps drag |
| NovaSeq X ramp (higher-margin consumables) | Accretive | +100–200 bps |
| Manufacturing efficiency | Accretive | +50–100 bps |
| China revenue decline | Slightly dilutive | ~30–50 bps |
| Product mix (consumable % rising) | Accretive | Structural tailwind |

Core gross margin expanded from ~60.9% (FY2023 trough, GRAIL-burdened) to 66.1% (FY2025, clean). Management targets 68–70% longer-term as NovaSeq X consumables mature.

---

#### Operating Expense Trends

| OpEx Category | FY2023 | FY2024 | FY2025 | Commentary |
|--------------|--------|--------|--------|-----------|
| R&D | $1,354M (30.1%) | $1,107M (25.3%) | $967M (22.3%) | Significant reduction post-GRAIL; right-sizing |
| SG&A | $1,108M (24.6%) | $1,062M (24.3%) | $1,086M (25.0%) | Relatively stable |
| Total OpEx | $2,462M (54.7%) | $2,169M (49.6%) | $2,053M (47.3%) | Positive leverage |

**Key insight:** R&D rationalization from 30% → 22% of revenue is the largest driver of the EBIT margin recovery. Management target is ~22–24% R&D long-term while maintaining innovation pace.

---

#### P&L Summary Table (FY2025 — Clean Year)

| Line Item | FY2025 | % of Revenue |
|-----------|--------|-------------|
| Revenue | $4,343M | 100.0% |
| Cost of Revenue | $(1,473M) | 33.9% |
| Gross Profit | $2,870M | 66.1% |
| R&D | $(967M) | 22.3% |
| SG&A | $(1,086M) | 25.0% |
| Total Operating Expenses | $(2,053M) | 47.3% |
| **EBIT** | **$807M** | **18.6%** |
| Interest Expense, net | ~$(55M) | |
| Other income | ~$100M | |
| Pre-tax Income | ~$852M | |
| Income Tax | ~$(2M) | |
| **Net Income** | **$850M** | **19.6%** |
| **Diluted EPS** | **$5.45** | |
| Diluted Shares | 156.0M | |

---

#### Key Financial Ratios (FY2025 / TTM)

| Ratio | FY2025 | TTM | Commentary |
|-------|--------|-----|-----------|
| Gross Margin | 66.1% | 66.2% | Expanding; target 68–70% |
| EBIT Margin | 18.6% | 19.4% | Recovery from GRAIL era; target 26% by 2027 |
| Net Margin | 19.6% | 19.4% | |
| FCF Margin | 21.4% | 22.2% | Strong; >100% net income conversion |
| FCF/Revenue | 21.4% | 22.2% | Exceptional for instruments company |
| R&D/Revenue | 22.3% | — | Well-funded innovation |

---

#### Financial Health Assessment

**Strengths:**
- Revenue stabilized at $4.3–4.4B; returning to growth in FY2026
- Gross margin recovery underway (60.9% trough → 66.1% → targeting 68–70%)
- FCF generation strong and improving ($283M → $709M → $931M in 3 years)
- Operating leverage now flowing through as GRAIL costs eliminated
- Balance sheet: $1.6B cash, $1.5B LT debt — manageable

**Risks:**
- Revenue near peak (FY2021 was $4.5B; FY2025 still slightly below)
- R&D cuts could be short-sighted if competitive threats accelerate
- SomaLogic integration adds complexity and integration risk to clean story
- China revenue headwinds persist

**Verdict:** The GAAP P&L is finally clean. Illumina's core economics — 66%+ gross margins, 22%+ EBIT margins on normalized basis, 21%+ FCF margins — are exceptional for an instrument company. The path to 26% EBIT margin (management 2027 target) is credible via continued consumable mix-up and OpEx leverage.

## Recent Catalysts

---
source: coverage-next-full
ticker: ILMN
step: "12"
title: Catalysts & Scenarios
created: 2026-05-29
---

### Step 12 — Catalysts & Scenarios

#### Near-Term Catalysts (6–18 months)

##### 1. FY2026 Revenue Guidance Achievement / Raise
- Management guided $4.5–4.6B (+4–6% YoY); upside to $4.65–4.7B would drive 5–8% stock appreciation
- Q2 2026 earnings (August 2026) will be the first meaningful test of full-year trajectory
- Consumable revenue per NovaSeq X instrument is the key watch metric

##### 2. Operating Margin Expansion Toward 26% Target
- Management 2027 target of 26% EBIT margin; any quarter printing 22–23%+ non-GAAP margins ahead of schedule drives re-rating
- R&D efficiency (22% of rev holding while absolute OpEx flat) + operating leverage from revenue growth = path to 24%+ in FY2026

##### 3. NovaSeq X Consumable Ramp — Gigabase Data Points
- Each quarterly earnings call includes gigabase shipment commentary
- Achieving >80% of gigabases from NovaSeq X would signal consumable monetization fully realized → consensus estimate upgrades

##### 4. Clinical Adoption Milestones (Population Programs)
- New national sequencing programs announcement (India, Saudi Arabia, UAE at scale)
- Expansions to existing programs (NHS England, US All of Us)
- Multi-year, high-volume contracts with major diagnostic labs (LabCorp, Quest equivalent outside US)

##### 5. SomaLogic Integration Progress (FY2026 H2)
- Successful product integration milestone: first combined "genomics + proteomics" offering commercially launched
- SomaLogic revenue contribution ramping above initial guidance (~$60–80M)
- Demonstration of multiomics synergy (e.g., partnership with Roche, AstraZeneca for integrated research workflows)

##### 6. China Stabilization / Resolution
- An unexpected improvement in US-China trade relations or removal from UEL list would be a $200–300M revenue upside catalyst
- Probability: LOW (~10–15%) in 12-month timeframe; but asymmetric upside if it occurs

##### 7. Capital Return Announcements
- Initiation of regular dividend (unlikely near-term, but would be a signal of FCF confidence)
- New/expanded buyback authorization (likely in 2027 as FCF grows further)
- Special dividend from excess cash balance

---

#### Medium-Term Catalysts (18–48 months)

##### 1. 2027 EBIT Margin Target Achievement
- 26% EBIT margin by 2027 = ~$1.2B EBIT on ~$4.8B revenue
- At 25x forward P/E (non-GAAP EPS ~$7.50) → stock price ~$187 (from current $158)
- At 30x P/E → $225 — significant upside if multiple expansion accompanies execution

##### 2. Long-Read Platform Response
- Illumina launching a credible long-read or hybrid platform would remove a significant overhang
- "Illumina Complete Long Read" commercial traction (current synthetic long-read approach) could prove viable

##### 3. AI-Genomics Demand Surge
- Major AI drug discovery programs (Isomorphic, Recursion, Genentech) ramping genomic data production
- Pharmaceutical companies building large-scale human genome databases as AI training data
- This could add 5–10%+ to consumable demand if the AI-genomics data flywheel accelerates

##### 4. Rare Disease WGS Standard-of-Care Shift
- If WGS becomes reimbursed first-line test for rare/undiagnosed disease patients (UK NICE precedent, US Medicaid expansion), this unlocks a large clinical volume
- ILMN would be the primary beneficiary; could add $300–500M to addressable market over 3–5 years

---

#### Scenario Analysis

##### Base Case (Probability: 55%)
- FY2026: Revenue $4.55B; EBIT margin 21–22%; EPS (non-GAAP) $5.10–5.20
- FY2027: Revenue $4.8B; EBIT margin 24–26%; EPS $6.50–7.00
- Multiple: 25–28x forward P/E
- **Price Target: $170–185 (12 months); $200–220 (24 months)**

##### Bull Case (Probability: 25%)
- NovaSeq X consumable ramp exceeds expectations; clinical segment grows 20%+
- SomaLogic integration creates differentiated multiomics revenue
- NIH headwinds resolve; research segment returns to growth
- 26% EBIT target achieved in FY2026 rather than FY2027
- Multiple: 30–33x forward P/E on premium growth/margin profile
- **Price Target: $210–235 (12 months); $250–280 (24 months)**

##### Bear Case (Probability: 20%)
- NIH cuts materialize more severely (-30% funding); research segment contracts 10%+
- China worsens beyond guidance; UEL restrictions expand
- Element Biosciences begins winning clinical lab tenders; installed base growth slows
- SomaLogic integration disappoints; margin expansion delayed
- Multiple: 20–22x forward P/E on slower growth
- **Price Target: $120–140 (12 months); $110–130 (24 months)**

---

**Bull Case**
- NovaSeq X consumable ramp accelerates faster than expected as large population sequencing programs scale globally, driving EBIT margins above 26% ahead of the 2027 target and triggering consensus EPS estimate upgrades of 15%+
- Clinical segment sustains 18–20% ex-China growth as whole-genome sequencing becomes reimbursed standard-of-care for rare disease and comprehensive genomic profiling expands, significantly outpacing the research headwind from NIH uncertainty
- SomaLogic proteomics integration proves strategically differentiated, attracting major pharma partnerships for multiomics research platforms that re-rate ILMN toward a 30–33x P/E multiple on growing out-year earnings

**Bear Case**
- NIH budget cuts of 25–35% materialize and persist for 2–3 years, reducing research-segment volumes materially while simultaneously signaling reduced government commitment to genomics programs globally, creating a compounding headwind to both top-line and narrative
- China regulatory situation deteriorates further — MOFCOM restrictions tighten or domestic MGI alternatives gain clinical certification — accelerating revenue erosion from the $210M FY2026 baseline toward near-zero contribution over 3 years with no offsetting regional acceleration
- Element Biosciences and Ultima Genomics secure their first FDA clearances for high-throughput clinical applications by 2027–2028, initiating a competitive dynamic in the most defensible segment of Illumina's installed base and triggering multiple compression from 28x to 18–20x forward earnings

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/ilmn
- Full research API: GET /api/v1/research/ILMN/memo
- Coverage universe: /stocks